search

Active clinical trials for "Astrocytoma"

Results 111-120 of 370

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

Adult Anaplastic AstrocytomaAdult Anaplastic Ependymoma3 more

This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma. Specialized radiation therapy, such as hypofractionated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving hypofractionated radiation therapy together with temozolomide and bevacizumab may kill more tumor cells.

Terminated31 enrollment criteria

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma...

Glioblastoma MultiformeGlioma2 more

Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary brain tumor are inadequate and as such, the median survival for most patients with GBM is on the order of months, even after cytoreductive surgery, radiation and chemotherapy. This study aims to develop a new treatment for GBM by suppressing glial progenitor cells that surround the ventricular system in patients with these aggressive tumors because it is these regions that appear to act as an incubator for future recurrences resulting in patient death. Considering the lack of significant treatment options for patients with this uniformly fatal disease, this is an important translational clinical study to perform.

Terminated25 enrollment criteria

Bortezomib in Treating Patients With Recurrent Glioma

Adult Anaplastic AstrocytomaAdult Anaplastic Oligodendroglioma4 more

Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

Terminated22 enrollment criteria

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

Anaplastic AstrocytomaAnaplastic Oligodendroglioma3 more

This phase I trial studies the side effects and best dose of ascorbic acid when given together with temozolomide in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid contains ingredients that may prevent or slow the growth of high-grade gliomas. Giving temozolomide with ascorbic acid may kill more tumor cells.

Terminated24 enrollment criteria

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory...

Childhood Choroid Plexus TumorChildhood Ependymoblastoma17 more

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Terminated46 enrollment criteria

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Low Grade GliomaWorld Health Organization (WHO) Grade II Astrocytomas2 more

The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.

Terminated29 enrollment criteria

Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic...

Glioblastoma (GBM)DIPG7 more

The standard therapy of glioblastoma (GBM) consists of gross total resection followed by focal irradiation to the tumor bed with concomitant and adjuvant temozolomide (TMZ). The association of valproic acid and TMZ during radiotherapy improves survival of GBM. Preclinical studies suggested that doxorubicin had a strong antineoplastic activity against human gliomas. Moreover, some studies showed that the continuous infusion of anthracyclines in patients with solid tumor ensured a better safety profile compared with bolus administration. Based on these findings, the purpose of this study is to evaluate safety and efficacy of prolonged administration of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in pediatric and adult patients with newly diagnosed GBM and diffuse intrinsic pontine glioma (DIPG).

Terminated15 enrollment criteria

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

Recurrent Glioblastoma Multiforme (GBM)Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma2 more

This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined. Part 2 will be a dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D). The RP2D is defined as the dose level recommended for further clinical study, or the highest dose tested.

Terminated28 enrollment criteria

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Brain TumorAnaplastic Astrocytoma7 more

RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ritonavir together with lopinavir works in treating patients with progressive or recurrent high-grade glioma.

Terminated20 enrollment criteria

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2...

Glioblastoma MultiformeAnaplastic Astrocytoma

The primary objectives of this study are to determine the maximal tolerated dose (MTD) of PAC-1 in combination with temozolomide in patients with high grade glioma: glioblastoma multiforme (GBM) or anaplastic astrocytoma after progression following standard first line therapy (Component 2), by evaluation of toxicity and tolerability.

Terminated36 enrollment criteria
1...111213...37

Need Help? Contact our team!


We'll reach out to this number within 24 hrs